Atea Pharmaceuticals (AVIR.US) will release its earnings report after market close on August 12.
Atea Pharmaceuticals (AVIR.US) is scheduled to release its earnings report after the market closes on August 12. This announcement provides investors with the specific date to anticipate the company's financial performance update.
Morgan Stanley Adjusts PT on Atea Pharmaceuticals to $7 From $6, Maintains Equalweight Rating
Morgan Stanley has increased its price target for Atea Pharmaceuticals (AVIR) to $7 from $6, while reiterating an "Equalweight" rating on the stock. This adjustment comes amidst recent company news, including Atea's Q2 2026 earnings call and positive topline results from its C-BEYOND Phase 3 trial for Hepatitis C. The firm's analysis reflects ongoing developments in Atea's pipeline of antiviral therapies.
Atea Pharmaceuticals Reports Q2 2026 Financials and Clinical Progress in Form 10-Q Filing
Atea Pharmaceuticals has filed its Q2 2026 Form 10-Q report, detailing its financial status, including 80,204,699 shares outstanding as of August 10, 2026. The company is actively pursuing two antiviral programs: the C-FORWARD Phase 3 clinical trial for Hepatitis C (HCV) with BEM/RZR, and clinical trials for AT-587 targeting Hepatitis E (HEV). Atea plans to submit a New Drug Application (NDA) to the FDA for the BEM/RZR regimen for HCV treatment.
Atea Pharmaceuticals (NASDAQ:AVIR) Releases Earnings Results, Beats Expectations By $0.15 EPS
Atea Pharmaceuticals (NASDAQ:AVIR) announced its quarterly earnings, reporting an EPS of ($0.41), surpassing the consensus estimate of ($0.56) by $0.15. The company's shares traded at $5.06, and it has a market capitalization of approximately $405 million. Analyst sentiment is divided, with one Strong Buy and one Sell rating, while institutional investors hold a significant portion of the stock.
ATEA PHARMACEUTICALS ($AVIR) Releases Q2 2026 Earnings
ATEA Pharmaceuticals ($AVIR) reported its Q2 2026 earnings, posting a loss of -$0.41 per share, significantly beating analyst estimates of -$0.57. The company's revenue matched estimates at $0. The article also details recent hedge fund activity for AVIR, showing institutional investors adding and decreasing shares in their portfolios.
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Atea Pharmaceuticals announced its second-quarter 2026 financial results, highlighting positive Phase 3 C-BEYOND trial results for BEM/RZR in treating HCV, which met primary and secondary endpoints. The company also provided updates on its C-FORWARD trial, expected in early Q1 2027, and advancements in its AT-587 Phase 1 trial for Hepatitis E Virus. Financially, Atea reported $219.5 million in cash and investments, with decreased R&D and G&A expenses compared to the previous year.
Atea Hepatitis C Regimen Posts 93.9% Sustained Response
Atea Pharmaceuticals reported Q2 2026 financial results, including a net loss of $32.9 million, and provided a business update highlighting progress in its viral hepatitis pipeline. The Phase 3 C-BEYOND trial for its HCV regimen (BEM/RZR) met primary and secondary non-inferiority endpoints with a 93.9% sustained virologic response. The company also announced the completion of enrollment for its C-FORWARD trial and the initiation of a Phase 1 trial for AT-587 for chronic HEV.
Atea Pharmaceuticals Leads Our Trio Of Promising Penny Stocks
This article identifies three promising penny stocks: Atea Pharmaceuticals (AVIR), Mammoth Energy Services (TUSK), and Tilly's (TLYS), highlighting their financial health and growth potential in a rising market. Atea Pharmaceuticals is noted for its strong cash position and positive trial results despite being pre-revenue. Mammoth Energy Services shows improved earnings despite past unprofitability, and Tilly's, while also unprofitable, reported increased sales and reduced net losses.
Arrowstreet Capital Limited Partnership Takes Position in Atea Pharmaceuticals, Inc. $AVIR
Arrowstreet Capital Limited Partnership has acquired a new position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR), purchasing 210,542 shares valued at approximately $1.13 million. This acquisition makes Arrowstreet Capital Limited Partnership one of several institutional investors increasing their stakes in the biopharmaceutical company, which now has 86.67% institutional ownership. Despite a mixed analyst sentiment, Atea Pharmaceuticals reported a narrower-than-expected quarterly loss and is focused on developing oral antiviral therapeutics.
Atea Pharmaceuticals, Inc. (AVIR) Stock Price, News, Quote & History
This Yahoo Finance page provides a comprehensive overview of Atea Pharmaceuticals, Inc. (AVIR) stock, including its current price, news, and historical data. It details the company's financial performance, analyst insights, and key statistics, along with a company profile outlining its biopharmaceutical focus. The page also features comparison tools for similar biotechnology companies.
Atea Pharmaceuticals Leads Our Trio Of Promising Penny Stocks
This article identifies three promising "penny stocks" with strong financial fundamentals and growth potential in a robust United States market. It highlights Atea Pharmaceuticals (AVIR), Mammoth Energy Services (TUSK), and Tilly's (TLYS), providing an overview of each company's operations, financial health, and recent performance. Despite some challenges like unprofitability, these companies are noted for factors such as strong cash positions, improving revenues, or strategic initiatives.
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
Atea Pharmaceuticals, Inc. announced it will host a conference call and audio webcast on August 12, 2026, at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2026, and provide a business update. The company is a late-stage clinical biopharmaceutical firm focusing on oral antiviral therapeutics for serious viral diseases, including hepatitis C and hepatitis E. Interested parties can register online or access the webcast via Atea's investor relations website.
Atea Pharmaceuticals to Host Second Quarter 2026 Financial
Atea Pharmaceuticals announced it will host a conference call and audio webcast on August 12, 2026, to report its second-quarter 2026 financial results and provide a business update. The event will cover the company's progress in developing oral antiviral therapeutics for serious viral diseases. Interested participants can register for the live conference call or access the webcast through Atea's investor relations website.
Atea's Aug. 12 webcast will include a business update
Atea Pharmaceuticals (Nasdaq: AVIR) will host a live conference call and audio webcast on Wednesday, August 12, 2026, at 4:30 p.m. ET to discuss its second quarter 2026 financial results and provide a business update. Investors can access the webcast through the Investor Relations section of Atea’s website or join by telephone. An archived webcast will be available for at least 90 days after the call.
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
Atea Pharmaceuticals, Inc. is projected to report a loss of 56 cents per share, according to an earnings preview. The full article is available to subscribers of TradingView, which aggregates content from Reuters and other news sources.
301,699 Shares in Atea Pharmaceuticals, Inc. $AVIR Bought by Irenic Capital Management LP
Irenic Capital Management LP recently acquired 301,699 shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) for approximately $1.62 million, increasing institutional ownership in the company to 86.67%. This purchase occurred as Atea Pharmaceuticals reported a quarterly loss of $0.57 per share, outperforming analyst estimates. The stock currently has a "Moderate Buy" consensus rating from analysts, with various other institutional investors also adjusting their stakes.
Atea Pharmaceuticals Inc (AVIR) Valuation: PE, PB & Fair Value Analysis
This article analyzes the valuation of Atea Pharmaceuticals Inc (AVIR), noting its current valuation score of 6.78, ranking it 260 out of 385 in the Biotechnology & Medical Research industry. It highlights AVIR's current P/E ratio of -2.22, which is significantly below its recent high and above its recent low. The article also states that relevant data for P/B and P/CF ratios have not been disclosed by the company.
Analysts Are Bullish on These Healthcare Stocks: Opko Health (OPK), Atea Pharmaceuticals (AVIR)
The article highlights bullish sentiments from analysts on several healthcare stocks, including Opko Health (OPK), Atea Pharmaceuticals (AVIR), and Monte Rosa Therapeutics (GLUE). H.C. Wainwright and Piper Sandler reiterated Buy ratings for Opko Health, William Blair maintained a Buy rating for Atea Pharmaceuticals, and LifeSci Capital and Guggenheim affirmed Buy ratings for Monte Rosa Therapeutics. The report details price targets and potential upsides for each company based on analyst consensus.
Atea Pharmaceuticals Shares Positive Results From Hepatitis C Trial
Atea Pharmaceuticals announced positive results from its Phase 2 clinical trial for a new hepatitis C treatment. The company's drug candidate demonstrated significant efficacy and safety in the study participants. This development could lead to a new treatment option for hepatitis C patients.
Atea drops despite late-stage trial win for hepatitis C therapy
Atea Pharmaceuticals (AVIR) announced positive topline data from its Phase 3 C-BEYOND study for its lead candidate BEM/RZR, demonstrating a late-stage trial win against chronic hepatitis C. Despite this clinical success, the company's stock traded lower on Tuesday. The drug is an antiviral therapy targeting a blood-borne liver infection.
Atea Pharmaceuticals Reports Positive Topline Results From C-BEYOND Phase 3 Trial Evaluating Bemnifosbuvir/Ruzasvir For Hepatitis C Virus
Atea Pharmaceuticals announced positive topline results from its C-BEYOND Phase 3 trial, showing its bemnifosbuvir/ruzasvir (BEM/RZR) combination achieved statistical non-inferiority against the standard treatment for chronic hepatitis C virus (HCV) infection. The BEM/RZR regimen demonstrated robust sustained virologic response rates, including in cirrhotic and non-cirrhotic patients, with a shorter 8-week treatment duration for non-cirrhotic individuals compared to the 12-week standard. The treatment proved generally safe and well-tolerated, reinforcing its potential as a differentiated and best-in-class option given its efficacy, shorter duration for most patients, and low drug-drug interaction risk.
Atea Pharmaceuticals Reports Positive Phase 3 C-BEYOND Results for Bemnifosbuvir/Ruzasvir in Hepatitis C, Achieving Non-Inferiority to Epclusa
Atea Pharmaceuticals announced positive results from its C-BEYOND Phase 3 clinical trial, demonstrating that bemnifosbuvir/ruzavir (BEM/RZR) achieved non-inferiority compared to standard-of-care sofosbuvir/velpatasvir (SOF/VEL) for chronic hepatitis C. BEM/RZR showed a high sustained virologic response rate of 93.9% with a shorter 8-week treatment duration for non-cirrhotic patients. The company plans to release results from its second Phase 3 trial, C-FORWARD, in early 2027, aiming to further contribute to HCV eradication efforts.
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
Atea Pharmaceuticals announced positive topline results from its Phase 3 C-BEYOND trial, demonstrating that its BEM/RZR treatment for hepatitis C virus (HCV) achieved statistical non-inferiority compared to a standard-of-care treatment. The study showed high cure rates, with a 93.9% sustained virologic response, and highlighted the potential for a shorter 8-week treatment duration for non-cirrhotic patients. These results position BEM/RZR as a potential best-in-class option for HCV, with data from another Phase 3 trial, C-FORWARD, expected in early 2027.
AVIR|Atea Pharmaceuticals Inc|Price:4.810|Chg%:+0.080
This article provides a comprehensive stock analysis of Atea Pharmaceuticals Inc (AVIR), detailing its TradingKey Stock Score, financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment. Key insights highlight the company's stable fundamentals, high growth potential, fair valuation, and strong institutional ownership, despite a projected short-term downward trend in stock price. The analysis includes a peer comparison within the Biotechnology & Medical Research industry and explains how various scores are generated.
Atea Pharmaceuticals Inc (AVIR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for Atea Pharmaceuticals Inc (AVIR), but notes that relevant data for business segments and regional revenue have not yet been disclosed by the company for fiscal years 2020 through 2022. It briefly shows the company's current stock price and market capitalization. The article indicates a lack of detailed financial segmentation information publicly available.
Atea Pharmaceuticals Inc (AVIR) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Atea Pharmaceuticals Inc (AVIR), highlighting its current earnings forecast score and analyst ratings. Based on three analysts, the average price target for AVIR is $6.00, with a consensus "Buy" rating. The article also discusses past EPS performance and future expectations.
[Press release] Atea Pharmaceuticals initiates first-in-human Phase 1 clinical trial of AT-587 for the treatment of hepatitis E virus
Atea Pharmaceuticals has announced the start of a first-in-human Phase 1 clinical trial for AT-587, an oral antiviral nucleotide analog designed to treat hepatitis E virus (HEV). The trial will assess the safety, tolerability, and pharmacokinetics of AT-587 in healthy volunteers, including single and multiple ascending dose components, and a food-effect assessment. HEV can lead to serious liver disease, chronic infection, cirrhosis, and liver failure in some patients.
AVIR|Atea Pharmaceuticals Inc|Price:4.730|Chg%:-0.020
Atea Pharmaceuticals Inc. (AVIR) is a clinical-stage biopharmaceutical company focused on developing oral antiviral therapies for serious viral infections, using a proprietary nucleos(t)ide prodrug platform. The company's lead program involves bemnifosbuvir and ruzasvir for hepatitis C virus (HCV) replication. As of the latest financial update, 228 institutions hold shares in Atea Pharmaceuticals, accounting for 70.93% of total shares.
AVIR|Atea Pharmaceuticals Inc|Price:4.730|Chg%:-0.020
Atea Pharmaceuticals Inc. (AVIR) closed at $4.73, down 0.42%, with a market cap of $378.53 million. TradingKey analysis indicates stable fundamentals, high growth potential, and a "fairly valued" status within the Biotechnology & Medical Research industry, despite a short-term trend expected to move downwards. Analysts have a "Buy" rating with an $8.00 price target, suggesting a 64.27% upside.
BML Capital Management LLC Sells 431,343 Shares of Atea Pharmaceuticals, Inc. $AVIR
BML Capital Management LLC reduced its stake in Atea Pharmaceuticals (NASDAQ:AVIR) by 5.8% in the first quarter, selling over 431,000 shares but still holding a significant position valued at $37.98 million. Despite this sale, Atea remains BML Capital's second-largest holding, comprising 24.4% of its portfolio. Other institutional investors like JPMorgan Chase, Millennium Management, and Goldman Sachs increased their holdings in the biopharmaceutical company, which recently reported better-than-expected EPS but faces mixed analyst ratings.
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
Atea Pharmaceuticals has announced the initiation of a first-in-human Phase 1 clinical trial for AT-587, an oral antiviral nucleotide analog designed to treat hepatitis E virus (HEV). This marks a significant step towards addressing the unmet medical need for HEV, especially in immunocompromised individuals, as there are currently no approved treatments. Preclinical data for AT-587 have shown potent antiviral activity against HEV, suggesting its potential as a first-in-class therapy.
William Blair Maintains Atea Pharmaceuticals(AVIR.US) With Buy Rating
William Blair has reiterated its Buy rating for Atea Pharmaceuticals (AVIR.US). The article does not provide further details on the rationale behind this rating or any specific financial analysis.
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
Atea Pharmaceuticals has started a first-in-human Phase 1 clinical trial for AT-587, an oral antiviral nucleotide analog designed to treat Hepatitis E Virus (HEV). This study aims to assess the safety, tolerability, and pharmacokinetics of AT-587 in healthy volunteers, addressing a critical unmet medical need as there are currently no approved treatments for HEV. Preclinical data has shown AT-587 to be a potent antiviral against HEV, with potential to become an important therapeutic option, particularly for immunocompromised patients at high risk for chronic infection.
Hepatitis E Has No Approved Treatments as Atea Begins Human Trial
Atea Pharmaceuticals (NASDAQ: AVIR) has initiated a Phase 1 clinical trial for AT-587, an oral nucleotide analog aimed at treating hepatitis E virus (HEV), a serious liver disease with no approved treatments. Preclinical studies showed that AT-587 is 30-150 times more potent than existing off-label treatments and effective against resistance strains, holding promise for immunocompromised patients at high risk. The trial will assess the safety, tolerability, and pharmacokinetics of AT-587 in healthy volunteers through single and multiple ascending dose components.
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
Atea Pharmaceuticals has initiated a Phase 1 clinical trial for AT-587, a potential first-in-class oral antiviral nucleotide analog for Hepatitis E Virus (HEV). This study will assess the safety, tolerability, and pharmacokinetics of AT-587 in healthy volunteers, aiming to address the significant unmet medical need for HEV, especially in immunocompromised patients. Preclinical data for AT-587 has shown potent antiviral activity against HEV and other flaviviruses.
Atea Pharmaceuticals (AVIR) Q1 2026 earnings summary
Atea Pharmaceuticals reported its Q1 2026 earnings, highlighting progress in two pivotal Phase 3 HCV trials with topline results expected mid to year-end 2026 and an NDA submission targeted for Q1 2027. The company expanded its antiviral pipeline to include AT-587 for chronic hepatitis E, with a Phase 1 initiation planned for mid-2026, and maintained a strong financial position with $256 million in cash, supporting operations through 2027 despite a net loss of $45.4 million.
Atea Pharmaceuticals (AVIR) Proxy filing Summary
Atea Pharmaceuticals (AVIR) has filed a proxy summary detailing its upcoming annual meeting on June 18, 2026. Key agenda items include the election of three Class III directors, ratification of KPMG LLP as the independent auditor, and an advisory vote on executive compensation. The company's strategic focus for 2025 involved advancing Phase 3 clinical trials for HCV, launching a new HEV candidate, and implementing a workforce reduction while completing a $25 million stock repurchase program.
Atea Pharmaceuticals (AVIR) Q2 2024 earnings summary
Atea Pharmaceuticals reported its Q2 2024 earnings, highlighting full enrollment in its Phase 3 SUNRISE-3 COVID-19 and Phase 2 HCV trials, with topline results expected in the second half of 2024. The company's cash position was $502.2 million as of June 30, 2024, projected to fund operations into 2027 despite an increased net loss of $40.5 million for the quarter. Atea also advanced its HCV program, selecting a fixed-dose combination and presenting positive data at EASL.
Atea Pharmaceuticals (AVIR) Q4 2025 earnings summary
Atea Pharmaceuticals reported its Q4 2025 earnings, highlighting an advanced global Phase III HCV program with topline results from C-BEYOND expected in mid-2026 and C-FORWARD by year-end 2026. The company also expanded its antiviral pipeline with an HEV program, expecting first-in-human studies for its lead candidate AT-587 by mid-2026. Atea maintains a strong financial position with $301.8 million in cash and equivalents, projected to support operations through 2027.
Atea Pharmaceuticals (AVIR) Q4 2025 earnings summary
Atea Pharmaceuticals released its Q4 2025 earnings summary, highlighting advancements in its Phase III HCV program with bemnifosbuvir/ruzasvir, which expects topline results mid-2026 and year-end 2026. The company also expanded its antiviral pipeline with an HEV program, anticipating first-in-human studies for AT-587 by mid-2026. Financially, Atea ended 2025 with $301.8 million in cash and equivalents, projects a cash runway through 2027, and plans for an NDA submission for its HCV regimen in Q1 2027.
Atea Pharmaceuticals (AVIR) 7th Annual Evercore ISI HealthCONx Healthcare Conference summary
Atea Pharmaceuticals (AVIR) presented key clinical data from its Phase 2 trials for bemnifosbuvir and ruzasvir in HCV at the 7th Annual Evercore ISI HealthCONx Healthcare Conference. The company reported 98% SVR12 in adherent patients and favorable safety, with plans for an end-of-Phase 2 FDA meeting in early Q1 2025 to discuss a global Phase 3 program. The market outlook for HCV treatment remains significant, and Atea is considering partnerships for commercialization while emphasizing the regimen's drug forgiveness and potential for improved adherence.
Atea Pharmaceuticals (AVIR) Q1 2026 earnings summary
Atea Pharmaceuticals reported its Q1 2026 earnings, detailing progress on two pivotal Phase 3 HCV trials (C-BEYOND and C-FORWARD) with topline results expected mid-2026 and year-end 2026, respectively, and a Q1 2027 NDA submission target. The company also expanded its antiviral pipeline with AT-587 for chronic hepatitis E, planning Phase 1 initiation for mid-2026. Atea recorded a net loss of $45.4 million for Q1 2026 but maintains a strong financial position with $256 million in cash, expected to fund operations through 2027.
Atea Pharmaceuticals (AVIR) Proxy filing Summary
Atea Pharmaceuticals (AVIR) has scheduled its Annual Meeting for June 18, 2026, where shareholders will vote on the election of three Class III directors, the ratification of KPMG LLP as the independent accounting firm, and the advisory approval of named executive officer compensation. The board recommends voting in favor of all nominees and proposals. Shareholders can vote online or virtually, with a deadline of June 17, 2026.
Atea Pharmaceuticals (AVIR) 44th Annual J.P. Morgan Healthcare Conference Summary
Atea Pharmaceuticals presented an update at the 44th Annual J.P. Morgan Healthcare Conference, detailing progress on its Hepatitis C (HCV) and Hepatitis E (HEV) programs. The company's HCV regimen, Bemnifosbuvir and ruzasvir, is in Phase III trials with top-line data expected in Q3 and Q4 2026, targeting a pan-genotypic label and over $1 billion in commercial opportunity. Additionally, a new HEV clinical candidate, AT-587, is moving towards proof-of-concept studies and a Phase 1 trial in mid-2026, addressing a significant unmet need in immunocompromised patients.
AVIR - Atea Pharmaceuticals Inc Short Interest
This article provides a detailed financial snapshot of Atea Pharmaceuticals Inc (AVIR), focusing on its short interest, key financial metrics, stock performance, and insider/institutional ownership. It includes information such as market capitalization, income, sales, price-to-book ratio, EPS, short float percentage, volatility, and various performance indicators over different periods.
AVIR - Atea Pharmaceuticals Inc Volatility & Greeks
This article provides a detailed financial overview of Atea Pharmaceuticals Inc (AVIR), including its stock performance, volatility, key financial ratios, and insider/institutional ownership. It highlights various metrics such as market capitalization, P/E ratio, sales, EPS growth rates, and analyst recommendations, offering a comprehensive snapshot for potential investors.
Price to earnings forward of Atea Pharmaceuticals, Inc. – NASDAQ:AVIR
This article provides financial information for Atea Pharmaceuticals, Inc. (NASDAQ: AVIR), focusing on its forward price-to-earnings ratio. It indicates that the market is currently closed with no trades. The content offers a brief financial overview within the TradingView platform.
Price to book forward of Atea Pharmaceuticals, Inc. – NASDAQ:AVIR
This article focuses on the "Price to book forward" metric for Atea Pharmaceuticals, Inc., traded on NASDAQ under the symbol AVIR. It appears to be a financial data page from TradingView, providing an overview of the company's financial information within that platform. The content primarily lists navigation and platform features rather than in-depth financial analysis.
Enterprise value to EBITDA forward of Atea Pharmaceuticals, Inc. – BOATS:AVIR
This article provides the enterprise value to EBITDA forward for Atea Pharmaceuticals, Inc. (AVIR) as part of the Blue Ocean Alternative Trade System (BOATS) on TradingView. It appears to be a financial data point without further analysis or context on its significance.
Enterprise value to revenue forward of Atea Pharmaceuticals, Inc. – NASDAQ:AVIR
This article provides a financial snapshot for Atea Pharmaceuticals, Inc. (NASDAQ: AVIR), focusing on its enterprise value to revenue forward. It appears to be a stub or a data point from a larger financial platform, indicating a value change and percentage change for a specific period. The content primarily shows the company's ticker, market, and a brief status, with no further analytical details.
